 1SPONSOR: The University of Chicago  
 PROTOCOL TITLE : A phase II prospective, open-label trial of perioperative combination 
nivolumab and ipilimumab in patients with re sectable malignant peritoneal mesothelioma.  
 Principal Investigator: Hedy Kindler, MD,  Professor of Medicine Section of Hematology/Oncology, Univer sity of Chicago Medical Center 
Tel: 773-702-0360 hkindler@medicine.bsd.uchicago.edu  
 
Co-Investigators: Divya Sood, MD Kiran Turaga, MD, MPH Aliya Husain, MD Oliver Eng, MD Samuel Armato, PhD Michael Drazer, MD Ankit Dhiman, MBBS Emily Fenton, PA Aytekin Oto, MD, MBA Carla Harmath, MD Aditya Juloori, MD  
Statistician: Mihai Giurcanu, PhD 
 Amendment: 4 Protocol Version Da te: September 21, 2022 
               
 2Table of Contents 
TRIAL SUMMARY  .....................................................................................................................  4 
1.0 TRIAL DESIGN ................................................................................................................  5 
1.1 Trial Design ...........................................................................................................................  5 
1.2 Trial Schema .........................................................................................................................  6 
2.0 OBJECTIVES  ...................................................................................................................  6 
2.1 Primary Objectives  ................................................................................................................  6 
2.2 Secondary  Objectives  ............................................................................................................  6 
2.3 Exploratory  Objectives  ..........................................................................................................  7 
3.0 BACKGROUND  ...............................................................................................................  7 
3.1 Pharmaceutical  and Therapeutic  Background  ........................................................................  7 
3.2 Rationale  ..............................................................................................................................  8 
3.2.1 Rationale  for the Trial and Selected Subject Populations  ........................................................................  8 
3.2.2 Rationale  for Endpoints  .........................................................................................................................  10 
4.0 SUBJECT SELECTION  AND WITHDRAWAL  .....................................................................  11 
4.1 Number of Subjects ............................................................................................................  11 
4.2 Gender, Age, Racial and Ethnic Origin of Subjects ...............................................................  11 
4.3 Inclusion Criteria .................................................................................................................  11 
4.4 Exclusion  Criteria ................................................................................................................  12 
4.5 Subject Identification  & Recruitment  ..................................................................................  14 
4.6 Location ..............................................................................................................................  14 
4.7 Discontinuation  of Study and Participant  Withdrawal  .........................................................  14 
5.0 TRIAL INTERVENTIONS  ................................................................................................  15 
5.1 Pre‐intervention  Testing .....................................................................................................  15 
5.2 Neoadjuvant  Nivolumab  and Ipilimumab  ............................................................................  15 
5.2.1 Drug Supply ............................................................................................................................... ............. 15 
5.2.2 Dose Selection ............................................................................................................................... ........ 15 
5.2.3 Dose Modification  ............................................................................................................................... ... 16 
5.3 Surgical Intervention  ...........................................................................................................  16 
5.4 Adjuvant  Nivolumab  and Ipilimumab  ..................................................................................  17 
6.0 ADDITIONAL  METHODOLOGY  ......................................................................................  17 
6.1 Trial Blinding/Masking  ........................................................................................................  17 
6.2 Randomization  or Treatment  Allocation  .............................................................................  17 
 36.3 Stratification  .......................................................................................................................  17 
6.4 Concomitant  Medications/Vaccinations  (allowed & prohibited)  .........................................  17 
6.4.1 Acceptable  Concomitant  Medications  ...................................................................................................  17 
6.4.2 Prohibited  Concomitant  Medications  ....................................................................................................  18 
6.5 Supportive  Care Guidelines  .................................................................................................  18 
6.6 Diet/Activity/Other  Considerations  ....................................................................................  21 
6.6.1 Diet ............................................................................................................................... .........................  21 
6.6.2 Contraception  ............................................................................................................................... ......... 21 
6.6.3 Use in Pregnancy  ............................................................................................................................... .... 21 
6.6.4 Use in Nursing Women ..........................................................................................................................  22 
6.7 Subject Withdrawal/Discontinuation  Criteria ......................................................................  22 
6.8 Clinical Criteria for Early Trial Termination  ..........................................................................  22 
7.0 TRIAL PROCEDURES  .....................................................................................................  23 
7.1 Flow Chart – Schedule  of Events ..........................................................................................  23 
7.1.1 Flow Chart for Screening,  Neoadjuvant,  and Surgery Phases ................................................................  23 
7.1.2 Flow Chart for Adjuvant and Post‐Treatment  Phases ............................................................................  25 
7.2 Informed  Consent ...............................................................................................................  26 
7.3 Inclusion/Exclusion  Criteria Review.....................................................................................  26 
7.4 Medical History ...................................................................................................................  26 
7.5 Prior and Concomitant  Medications  Review ........................................................................  26 
7.5.1 Prior Medications  ............................................................................................................................... ... 26 
7.5.2 Concomitant  Medications.................................................................................................................... .. 27 
7.6 Disease Details and Treatments  ..........................................................................................  27 
7.6.1 Disease Details ............................................................................................................................... ........ 27 
7.6.2 Prior Treatment  Details .........................................................................................................................  27 
7.6.3 Subsequent  Anti‐Cancer Therapy Status ...............................................................................................  27 
7.7 Adverse Event (AE) Monitoring  ...........................................................................................  27 
7.8 Full Physical Exam ...............................................................................................................  27 
7.9 Vital Signs ...........................................................................................................................  27 
7.10 Eastern Cooperative  Oncology  Group (ECOG) Performance  Scale ........................................  28 
7.11 Tumor Imaging and Assessment  of Disease .........................................................................  28 
7.12 Tumor Tissue Collection  and Correlative  Studies Blood Sampling  ........................................  28 
7.13 Laboratory  Procedures/Assessments  ..................................................................................  28 
7.14 Safety Follow‐Up Visit .........................................................................................................  29 
7.15 Follow‐up Visits ..................................................................................................................  29 
7.16 Survival Follow‐up ..............................................................................................................  29 
 47.17 Assessing  and Recording  Adverse Events ............................................................................  29 
7.17.1  Adverse Event Characteristics  ...........................................................................................................  29 
7.17.2  Adverse Event Definitions  .................................................................................................................  30 
7.17.3  Evaluating  Adverse Events.................................................................................................................  31 
7.17.4  Responsibility  for Reporting  Adverse Events .....................................................................................  33 
8.0 STATISTICAL  ANALYSIS  PLAN .......................................................................................  33 
8.1 Primary Endpoint  ................................................................................................................  33 
8.2 Secondary  Endpoints  ..........................................................................................................  33 
8.3 Exploratory  Endpoints  .........................................................................................................  33 
9.0 LABELING,  PACKAGING,  STORAGE  AND RETURN OF CLINICAL SUPPLIES  ......................  34 
9.1 Investigational  Product .......................................................................................................  34 
9.2 Packaging  and Labeling Information  ....................................................................................  34 
9.3 Clinical Supplies Disclosure  .................................................................................................  34 
9.4 Storage and Handling Requirements  ...................................................................................  34 
10.0 ADMINISTRATIVE  AND REGULATORY  DETAILS ............................................................  34 
10.1 Confidentiality  ....................................................................................................................  34 
10.2 Compliance  with Financial Disclosure  Requirements  ...........................................................  34 
10.3 Compliance  with Law, Audit and Debarment  ......................................................................  35 
10.4 Compliance  with Trial Registration  and Results Posting Requirements  ................................  35 
10.5 Quality Management  System ..............................................................................................  35 
10.6 Data Management  ..............................................................................................................  35 
11.0 REFERENCES  ................................................................................................................  35 
12.0 APPENDIX  ...................................................................................................................  40 
12.1 ECOG Performance  Status ...................................................................................................  40 
12.2 Common  Terminology  Criteria for Adverse Events V5.0 (CTCAE) .........................................  40 
12.3 Prescribing  Information  ......................................................................................................  40 
12.3.1  Nivolumab  ............................................................................................................................... .......... 40 
12.3.2  Ipilimumab..................................................................................................................... ....................  40 
12.4 EORTC QOL‐C30 Quality of Life Survey ................................................................................  40 
 
 
 
TRIAL SUMMARY 
Abbreviated Title Nivolumab and Ipilimumab in resectable peritoneal mesothelioma 
 5Trial Phase Phase II 
Clinical Indication Malignant peritoneal mesothelioma 
Trial Type Treatment 
Type of control None 
Route of administration Intravenous 
Trial Blinding None 
Treatment Groups  1 
Number of trial subjects 37 subjects 
Estimated enrollment period 24 months 
Estimated duration of trial 42 months 
Duration of Participation  18 months 
 
 
 
 1.0 TRIAL DESIGN 
1.1 Trial Design  
This is a single institution, singl e-arm, phase II trial of perioper ative combinati on immunotherapy 
(nivolumab + ipilimumab) in patients with rese ctable malignant peritoneal mesothelioma. All 
patients will undergo pretreatment cross-sectional imaging (CT or MRI) for clinical staging, as 
well as a laparoscopy to stage the peritoneum, asse ss resectability, and acquire pretreatment tissue, 
all of which is part of standard of care. Enrolled  patients will then receiv e neoadjuvant combination 
immunotherapy, which will include 2 doses of nivol umab (3 mg/kg IV every 21 days) and 1 cycle 
of ipilimumab (1 mg/kg IV ). Repeat cross-se ctional imaging (CT or MR I) will be performed to 
assess response to neoadjuvant immunotherapy. Su rgical intervention via cytoreductive surgery 
(CRS) and hyperthermic intraperitoneal chemope rfusion (HIPEC) with mitomycin-C will occur 2-
6 weeks following the last dose of  the neoadjuvant therapy, at wh ich point additio nal pathologic 
assessments will be made. About 6-8 weeks following surgery and after new baseline cross-sectional imaging is completed, patients will re ceive adjuvant ipilimuma b (2 cycles; 1mg/kg IV 
every 6 weeks) + nivolumab (1 year). Restaging cross sectional scans will be obtained to assess 
response every 6 weeks while on adj uvant therapy and every 3 months for an additional year after 
completing therapy.  
The primary objective of the study is to assess the rate of majo r pathologic response (MPR), 
defined as 10% residual viable tumor (RVT) in th e resected surgical specimen following 
neoadjuvant nivolumab + ipilimu mab. Secondary objectives include  assessment of  the safety 
profile and feasibility of the neoadjuvant regimen, radiologic re sponse rate, and overall and 
progression-free survival. Samples will be obtained pretreatment via laparoscopy and after nivolumab + ipilimumab trea tment at surgical resection. Additio nal correlatives will be assessed 
including immune status/infiltration of the tumo r, CA-125 serum levels, serum SRMP (soluble 
mesothelin-related peptide), circulating tumo r cells, as well as ra diologic correlatives. 
 
 61.2 Trial Schema 
 
 
2.0 OBJECTIVES 
2.1 Primary Objectives 
1. To determine pathologic re sponse of the tumor to ne oadjuvant treatment with 
nivolumab + ipilimumab vi a Major Pathologic Response (MPR), defined as ≤10% 
residual viable tumor (RVT) cells, as  well as grade, necrosis, and Ki67. 
2.2 Secondary Objectives  
1. To determine the safety pr ofile of neoadjuvant nivolum ab + ipilimumab, as defined 
by rate of grade III/IV adverse events according to CTCAE v5.0, occurring up to 30 days post-operatively.  
2. To determine feasibility of neoadjuvant ni volumab + ipilimumab, as measured by the 
number of participants who complete ne oadjuvant treatment with nivolumab + 
ipilimumab and proceed to surgery without extended treatment-related delay (> 6-
week delay) or progre ssion precluding surgery.  
 
3. To determine the Overall Survival (OS)  effect from neoadjuvant nivolumab + 
ipilimumab, defined as time from enrollment on study to de ath from any cause.   
 
4. To determine the Progression-free Survival (PFS) effect from ne oadjuvant nivolumab 
+ ipilimumab, defined as tim e from enrollment on study to disease progression or 
death.  
 Malignant  
Peritoneal  
Mesothelioma
All histologies
18 yrs
ECOG < 2
No IO/chemo  within 4 
weeks
EXCLUSION:
Not a candidate  for 
CRS/HIPEC
Visceral metastasesBaseline 
imaging, labs
Staging 
laparoscopy  
and biopsyE
N
R
O
L
L
M
E
N
TNeoadjuvant  
IO
Nivolumab  IV 
3mg/kg Q3wks x2 + 
Ipilimumab  1mg/kg 
Q6wks x1
Restaging
Radiologic  
reassessment  after 
Nivo x2 and Ipi x1Restaging  
Radiologic  
assessment  (ORR by 
RECIST 1.1)
CRS/HIPEC
Pathologic  
assessment  (MPR, 
grade, necrosis, 
Ki67, immune 
infiltrate)Adjuvant 
IO
Nivolumab  IV 
3mg/kg Q3wks 
x1yr + 
Ipilimumab  
1mg/kg Q6wks
x2 cyclesFollow‐up
H&P, Labs, 
Imaging Q3mo 
x1 yr
 75. To determine the safety profile of ad juvant nivolumab + ipilimumab after 
cytoreductive surgery and HIPEC.  
 
6. To determine the radiologic response to neoadjuvant nivolumab + ipilimumab 
utilizing RECIST 1.1 pre- and post-treatment. 
 
7. To determine the effect of  neoadjuvant nivolumab + ipilimumab on peritoneal 
carcinomatosis index (PCI).  
 
2.3 Exploratory Objectives 
1. To determine immune status /infiltration of the tumor in  response to neoadjuvant 
nivolumab + ipilimumab, incl uding the change in pres ence of TILs/macrophages 
(CD3, CD4, CD8, CD11b, CD68, CD 20) and PDL1 status.  
 
2. To determine blood-based changes with nivolumab + ipilimumab treatment, 
including PBMC inflammation expressi on profile, serum mesothelin (SMRP), 
osteopontin, CA-125, and circulating tumor cells. 
 
3. To evaluate health-related quality of life (HRQoL) for patients with peritoneal 
mesothelioma undergoing perioperative immunotherapy, measured by the EORTC 
QLQ C30, which was developed specifically to assess quality of life in patients with 
cancer.  
 
4. To correlate radiologic tu mor measurements based on RECIST 1.1 and tumor volume 
with patient survival.  
 
5. To relate pathologic assessment of immune infiltrate with pre-operative image-based 
tumor signatures.  
 
6. To assess the response of neoadjuvant imm unotherapy in those w ith BAP1 mutations 
identified on next-g eneration sequencing.  
 3.0 BACKGROUND 
3.1 Pharmaceutical and Therapeutic Background  
The importance of intact immune surveillan ce in controlling outgrowth of neoplastic 
transformation has been known for decades.  Ac cumulating evidence shows a correlation between 
tumor-infiltrating lymphocytes (TILs) in can cer tissue and favorable  prognosis in various 
malignancies.  In particular, the presence of CD8+ T-cells and the ra tio of CD8+ effector T-cells / 
FoxP3+ regulatory T-cells seems to correlate with improved prognos is and long-term survival in 
many solid tumors (Facciabene, 2012).  
The PD-1 receptor-ligand interaction is a majo r pathway hijacked by tumors to suppress immune 
control.  The normal function of  PD-1, expressed on the cell su rface of activated T-cells under 
 8healthy conditions, is to down-regulate unwanted or excessive immune respons es.  PD-1 is an Ig 
superfamily member related to CD28 and CTLA-4 that has been shown to negatively regulate 
antigen receptor signaling upon engagement of its ligands (PD-L1 and/or PD-L2).   
PD-1 was shown to be expressed on activated ly mphocytes including periph eral CD4+ and CD8+ 
T-cells, B-cells, T regs and Natural Killer cells.  Expression has also been shown during thymic 
development on CD4-CD8- (double negative) T-cells as well as  subsets of macrophages and 
dendritic cells.  The ligands for PD-1 are constitutively expressed or  can be induced in a variety of 
cell types, including non-hematopoieti c tissues as well as in various tumors.  Binding of either PD-
1 ligand to PD-1 inhibits T-cell activation triggered th rough the T-cell receptor.   
Although healthy organs express litt le (if any) PD-L1, a variety of cancers were demonstrated to 
express abundant levels of this  T-cell inhibitor.  PD -1 has been suggested  to regulate tumor-
specific T-cell expansion in subj ects with melanoma, consistent with the understa nding that the 
PD-1/PD-L1 pathway plays a critical role in tumo r immune evasion and ther eby is an attractive 
target for therapeutic intervention. 
Nivolumab is a potent human i mmunoglobulin G4 (IgG4) monocl onal antibody (mAb) that binds 
to the PD-1 receptor and blocks its interacti on with PD-L1 and PD-L2, releasing PD-1 pathway-
mediated inhibition of the im mune response, including the anti-tumor immune response. 
The mechanism by which PD-1 down- modulates T-cell responses is similar to, but distinct from 
that of CTLA-4 as both molecule s regulate an overlappi ng set of signaling pr oteins.  CTLA-4 is 
a negative regulator of T-cell act ivity. Ipilimumab is a monoclona l antibody that binds to CTLA-
4 and blocks the interaction of  CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has 
been shown to augment T-cel l activation and proliferati on, including the activation and 
proliferation of tumor infiltra ting T-effector cells. Inhibiti on of CTLA-4 signaling can also 
reduce T-regulatory cell function, which may contribute to a general increase in T cell 
responsiveness, including the anti-tumor immune response. 
 
Combined nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) mediated inhibition has also 
been shown to result in enhanced T-cell function that is greater th an the effects of either antibody 
alone, suggesting a synergistic effect of the co mbination, and results in  improved anti-tumor 
responses in metastatic melano ma and advanced RCC. In murine  syngeneic tumor models, dual 
blockade of PD-1 and CTLA-4 resulted in increased anti-tumor activity (Fiegle, 2019). 
 
3.2 Rationale 
3.2.1 Rationale for the Trial and Selected Subject Populations 
Around 500-800 new cases of peritoneal mesothelio ma occur every year in the United States 
(Miura, 2014). In contrast to pleural mesothelio ma, an antecedent exposu re to asbestos cannot 
always be found in patients with this disease. Ho wever, we previously demonstrated that germline 
mutations (with BAP1  mutations being most common) are f ound in as many as 25% of peritoneal 
mesothelioma patients, compared  to only 7% of those with pl eural disease (Panou, 2018), implying 
that inherited susceptibility may play a larger role  in peritoneal mesothelioma. Patients generally 
present with ascites or malignant  bowel obstructions, which are sign ificantly life limiting due to 
the resulting malnutrition and inanition. Cross s ectional imaging such as CT scans or MRIs are 
 9utilized in the diagnosis of pe ritoneal mesothelioma but they generally unde restimate the burden 
of disease. There are 3 major histologic subtypes  of mesothelioma: epithelial, sarcomatoid, and 
mixed or biphasic (Husain, 2009).  Pathologic subtype is one of  the most important prognostic 
indicators in this disease, so  an accurate determination of pa thology is essential (Rusch, 2012).  
The prognosis of patients with pe ritoneal mesothelioma  is rather dismal in the absence of 
treatment, with a median surviv al of 12 months (Alexander, 2013). The standard of care for 
patients with peritoneal mesothelioma is the performance of cytoreductive surgery (CRS) and 
hyperthermic intra-peritoneal ch emotherapy (HIPEC). The surger y consists of extirpation of 
peritoneal tumor with parietal and visceral per itonectomy procedures and visceral resections as 
necessary. During the surgery, th e burden of disease is assessed by the peritoneal cancer index 
(PCI score). This score is meas ured by dividing the abdomen into  13 zones (including 4 zones for 
the bowel) and ranges from 0-39 ( 39 being the most disease). At  the end of the operation the 
residual tumor is assesse d by the completene ss of cytoreduction which is an important prognostic 
factor for the survival of these patients. Heated chemotherapy is then applied to the peritoneal 
surfaces for 90 minutes and circul ated at 600 ml-1500ml/min at 42 0C (Turaga K 2016).  
Patients undergoing CRS+HIPEC have an overall medi an survival of 53 months, with a more 
favorable prognosis for patients that undergo a complete cytoreduction (CC-0/1)(Yan TD 2009). 
The agent of choice for the intra-operativ e chemotherapy is either platinum based 
(cisplatin/carboplatin) or mitomycin C (Helm, 2 015). Grade III-IV complica tion rates after this 
surgery can be as high as 31-40% (Kepenek ian 2016). Major complications include death, 
anastomotic leak, deep or superficial site inf ection, anemia, re-operations , organ failure including 
renal failure, cardiac failure or  respiratory failure, neutrope nia, thromboembolic events, 
dehydration and failure to thrive.  
Due to the relatively low incidence of perito neal mesothelioma, ther e are no large randomized 
controlled trials for either surgery or chem otherapy to guide management, leaving no clear 
consensus on optimal treatment approach. Therefor e, much of the management is extrapolated 
from the studies in pleural mesothelioma. Standard chemotherapy for pleural mesothelioma consists of pemetrexed plus cisplatin.  This regimen was FDA-approved for MM based on a single-
blind, placebo-controlled, phase I II trial, which randomized 456 pati ents to cisplatin with or 
without pemetrexed. Patients wh o received the combination ach ieved a longer median overall 
survival (12.1 vs. 9.3 months, p = 0.020), a superior time to pr ogression (5.7 vs. 3.9 months, 
p = 0.001), and a higher objective re sponse rate (41% vs. 17%, p < 0.001) than patients who 
received cisplatin alone (Vogelzang, 2003).   However, the benefits of cytotoxic chemotherapy for peritoneal mesothelioma are less clear and 
alternative therapies such as immunotherapy wa rrant investigation. PD-1/PD-L1 and CTLA4 are 
immune checkpoints that mediate immune evasion in  a wide spectrum of tumors. While the normal 
function of PD-1 and CTLA4 is to counteract exce ssive immune responses di rected against normal 
tissues, various types of cancer ha ve manipulated this function by up-regulating the natural ligands 
of these checkpoints to evade i mmune recognition. The critical ro le of this pathway became 
evident with the promising results of clinical trials of PD-1/PD-L1  and CTLA4 inhibitors, such as 
pembrolizumab (Hamid, 2013), nivolumab (Wolchok, 2013), and MPDL3280A (Powderly, 2013). 
While immune checkpoint blockers have not been evaluated in me sothelioma in the neoadjuvant 
setting, they are being used safe ly in the preoperative setting in a variety of tumor types. 
 10In an analysis presented at ASCO 2014 (Kindler , 2014), we analyzed gene expression data on 44 
malignant mesothelioma tumors (Gordon, 2005), a pplied a melanoma-derive d signature of T-cell 
inflammation (Harlin, 2009), and analyzed other immune response related genes. We identified 
that 32% of malignant mesotheliomas showed hi gh CD8 gene expression, and a T-cell inflamed 
phenotype analogous to melanomas wa s present in multiple tumors. 
 We evaluated MM tumor tissues  from patients by multi-color  immunohistochemistry (IHC), 
staining for CD68 (macrophages), CD8 (tumor infiltrating lym phocytes), and PD-L1 (immune 
checkpoint, MTA: Lieping Chen) We obser ved PD-L1 expression in 75% of MM  tumors tested, 
which was 2-3+ in 37.5%, and 1+ in 37.5%. Pa tchy higher level PD-L1 expression was observed 
in stromal or CD68 cells located close to CD8+ cells. CD8 tumor infiltrating lymphocytes (TILs) 
were present in all epithelial tumors. Prominen t CD68 infiltration was seen in all tumors.  
Thus, we identified high PDL- 1 expression, a CD8 infiltrative pa ttern with a T-cell inflamed 
expression, and presence of PD-1/PD-L1 immune checkpoints in a subset  of MM (approximately 
1/3 of MM tumors) similar to the phenotype found in  other tumors such as melanoma that benefit 
from immune checkpoint blockade.  Furthermore, we recently identified a marked heterogeneity 
in PD-L1 expression speci fically in peritoneal mesothelioma a ssociated with either systemic or 
intraperitoneal chemothe rapy administration (White , 2020). This demonstrates  the pliability of 
PD-L1 as a biomarker, indicating th at a low PD-L1 status at a singl e timepoint should not preclude 
patients from immune chec kpoint inhibition therapy. 
 Based on these and other studies, MM is an ideal ta rget disease for anti-PD-1 therapy, and further 
investigation of the biology of th is agent in this disease is wa rranted. This hypothesis is further 
supported by the recently reported data from th e CheckMate 743 study. This was a randomized, 
open-label trial in patients with unresectable malignant pleural mesothelioma, with a primary 
endpoint of overall survival. Patients were randomized to receive either combination 
immunotherapy with nivolumab + ipilimumab for up to 2 years or  standard chemotherapy with 
pemetrexed + either cisplatin or  carboplatin for 6 cycles. The tr ial demonstrated a statistically 
significant improvement in OS for patients randomized to immunotherapy compared to chemotherapy. While it was efficaci ous in all histologies , there was a greater benefit noted in the 
sarcomatoid subgroup. The results of this trial have established a new standard of care in the 
treatment of malignant pleural mesothelioma, with immunotherapy now considered first line 
therapy. (Baas 2020).  Therefore, we expect to see a si milar response to imm unotherapy in the periton eal disease setting, 
and with this study we aim to evaluate that respon se. Of note, while resection is typically offered 
only to patients with non-sarcomat oid histology, in this trial we  plan to include sarcomatoid 
histologies as well. Due to the robust response in the CheckMate  743 trial, which demonstrated 
that immunotherapy allowe d for an equivalent survival in the sarcomatoid cohort to the epithelioid 
cohort, we anticipate that the sarcomatoid periton eal patients will have a similar response, making 
their disease more amen able to cytoreduction.  
 
3.2.2 
Rationale for Endpoints 
Tumor response is a surrogate mark er of benefit from immune ther apies that has been used for 
studies with nivolumab, ipilimum ab, and other immune therapie s. Response is considered a 
reliable marker of benefit for malignant mesothelioma and correlates with a survival benefit 
 11(Blayney, 2012). Response in pleural mesothelio ma is generally assessed via the modified 
RECIST 1.1 criteria for assessm ent of response in mesothelioma (Armat o 2018).  However, 
radiologic assessments of tumor response in per itoneal disease are poor and usually underestimate 
the burden of disease. 
Retrospective analyses have re vealed that Ma jor Pathologic Response (M PR) after neoadjuvant 
chemotherapy was related to improved overall survival and disease-free survival. Chaft et 
al. examined neoadjuvant chemotherapy for non -squamous NSCLC (non-sm all cell lung cancer) 
and reported that 22% of tumors showed MPR, w ith these responses being associated with long-
term survival. Furthermore, MPR has since been  used in several pros pective and randomized 
studies and has now been recomm ended as a surrogate endpoint sp ecifically in th e context of 
neoadjuvant immunotherapy (Hellmann, 2014). Pa thologic responses, such as MPR and 
pathologic complete response are to date the most commonly used metrics for assessing response 
to neoadjuvant immunotherapy, and have been used in trials for melanoma , colon cancer, NSCLC, 
muscle-invasive bladder cancer, and several ot hers (Chalabi, 2020; Yang, 2020). Patients with 
non-small cell lung cancer who rece ived neoadjuvant nivolumab were found to have a 45% rate 
of MPR (Bott, 2019), and 30% of those with res ectable stage III/IV mela noma who received just 
a single dose of pembrolizumab had MPR, 100% of which had a durable disease-free survival at 
24 months (Huang, 2019). This pa thologic response is seen not only in those with known 
susceptibility to immunotherapy, such as those with mismatch repair deficient (dMMR) tumors. 
In the NICHE study, though colorect al cancer patients with dMMR  tumors had a 95% MPR rate, 
those with MMR-proficient tumors still had a robust res ponse with 20% MPR rate  (Chalabi, 2020).  
 4.0 SUBJECT SELECTION AND WITHDRAWAL 
4.1 Number of Subjects 
This is a single-center phase II study and will enroll 37 patients for a total of 42 months. The 
University of Chicago will attempt to enroll 18-19  patients each year for two consecutive years. 
4.2 Gender, Age, Racial and Ethnic Origin of Subjects 
Both male and female patients who are at least 18 years of  age, of any ethnic  or racial background, 
are included. Children ( ≤18 years of age) will be excluded from this study to limit variability in 
the study population and avoid this vulnerable popul ation. There is no restriction on the racial or 
ethnic origin of subjects. Please see the inclus ion and exclusion criteria for full details. 
Prospective approval of protocol deviations to recruitment and en rollment criteria,  also known as 
protocol waivers or exem ptions, is not permitted. 
4.3 Inclusion Criteria 
In order to be eligible for participa tion in this trial, the subject must: 
1. Have a diagnosis of histologically or cytologi cally confirmed periton eal mesothelioma, of 
epithelial, biphasic, or  sarcomatoid subtypes 
 
2. Have disease burden amenable to cytore duction and hyperthermic intraperitoneal 
chemotherapy (HIPEC), as de termined by a surgeon special izing in mesothelioma  
 12 
3. Have measurable or evaluable diseas e based on RECIST 1.1 or on laparoscopy 
 
4. Have no definitive evidence of vis ceral metastases by best staging 
 
5. Be willing to undergo laparoscopy or mini- laparotomy for peritoneal staging 
 
6. Demonstrate adequate organ f unction as determined by scre ening labs, with criteria 
defined in Table 1 
 Table 1.  Adequate Organ Func tion Laboratory Values 
System Laboratory Value 
Hematological   
Absolute neutrophil count (ANC) ≥ 1,500 /L 
Platelets ≥ 100,000 / L 
Hemoglobin ≥ 9 g/dL  
Renal  
Serum creatinine OR 
Measured or calculateda 
creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤ 1.5 X upper limit of normal (ULN) OR 
 
≥ 60 mL/min for subject with creatinine levels > 
1.5 X institutional ULN 
Hepatic  
Serum total bilirubin ≤ 1.5 X ULN 
AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN   
Coagulation 
International Normalized Ratio 
(INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT)  
≤ 1.5 X ULN. Patients on anticoagulation are 
expected to hold anticoagu lation for at least 5 days 
prior to surgery. 
aCreatinine clearance should be calcu lated per institutional standard. 
 
7. Have an ECOG performance status of < 2 
 
8. Be  18 years of age on day of signing informed consent 
 
9. Be willing and able to provide written informed consent for the trial 
4.4 Exclusion Criteria 
The subject must be excluded from partic ipating in the trial if the subject:  
1. Is currently participating in a study of an  investigational agent and received an 
investigational agent within 4 weeks of th e first dose of treatm ent on this protocol 
 
2. Has received any immunotherapy agents outside of  this protocol within  4 weeks of the first 
dose of treatment on this protocol  
 133. Has a diagnosis of immunodeficien cy or is receiving chronic systemic steroid therapy (>10 
mg of prednisone daily or equivalent) or any other form  of immunosuppressive therapy 
within 14 days prior to the first dose of study drug.  
4. Has a known history of active TB infection (Bacillus tuberculosis) 
 
5. Has active COVID-19 infection 
 
6. Has known history of, or any evidence of activ e, non-infectious pneumonitis that required 
steroids, or ac tive pneumonitis 
 
7. Has a severe hypersensitivity to nivol umab or any of its excipients 
 
8. Has a severe hypersensitivity to ipilim umab or any of its excipients  
 
9. Has an active autoimmune disease that has requ ired systemic treatment in the past 2 years 
(i.e. with use of disease m odifying agents, corticosteroid s or immunosuppressive drugs) 
 
10. Has a known additional malignancy that is prog ressing or required active treatment within 
the 3 years prior to enrollment - exceptions in clude basal cell carcinoma of the skin or 
squamous cell carcinoma of the skin that ha s undergone potentially cu rative therapy or in 
situ cervical cancer or other tumors th at will not affect life expectancy 
 
11. Has an active infection re quiring systemic therapy 
 
12. Has a known history of HIV, Hepatitis B, or Hepatitis C 
 
13. Has known psychiatric or substa nce abuse disorders that woul d interfere with cooperation 
with the requirements of the trial.  
14. Is pregnant or breastfeeding, or expecting to  conceive or father children within the 
projected duration of the trial,  starting with the screening vi sit through 120 days after the 
last dose of trial treatment 
a. Female subjects of childbearing pote ntial should have a negative urine 
or serum pregnancy within  72 hours prior to rece iving the first dose of 
study medication.  If the urine test is positive or cannot be confirmed as 
negative, a serum pregnancy te st will be required.   
 
b. Female subjects of childbearing pote ntial should be willing to use 2 
methods of birth control or be su rgically sterile, or abstain from 
heterosexual activity for the course of the study through 120 days after 
the last dose of study medication (R eference Section 5.8.2).  Subjects of 
childbearing potential are those who ha ve not been surgically sterilized 
or have not been free from  menses for > 1 year.  
 
 14c. Male subjects should agree to use an adequate method of contraception 
starting with the first dose of study therapy thro ugh 120 days after the 
last dose of study therapy.  
15. Is on anticoagulation that cannot be di scontinued in the pe rioperative period 
 
16. Has received a live vaccine within 30 days of planned start of study therapy 
4.5 Subject Identification & Recruitment  
Patients will be identified duri ng the initial medical oncology or surgical oncology appointment. 
Patients will be screened for the appropriate inclus ion and exclusion criteria and recruited to the 
trial as appropriate. There will be no use of advertisements, bu t it will be listed on the Cancer 
Center website. Patients will not be id entified through medical records.  
4.6 Location  
This trial will be a single instit ution study. Recruitment of all patie nts will happen at the University 
of Chicago main site. Patients will undergo all inte rventions at the University of Chicago main 
site, but may receive the immunotherapy at the satellite sites.  
4.7 Discontinuation of Study and Participant Withdrawal  
Discontinuation of study intervention does not represent withdrawal from the study. 
As data on clinical events beyond study intervention discontinuation may be important to the study, 
they must be collected through th e participant’s last scheduled fo llow up, even if the participant 
has discontinued study intervention. Therefore, all participants who discontinue study intervention 
prior to completion of the protocol-specified treatme nt period will still continue to participate in 
the study.  Participants may discontinue study intervention at  any time for any reason or be discontinued from 
the study intervention at the discretio n of the investigator should a ny untoward effect occur. Also, 
a participant may be discontinued from study inte rvention by the investigator if study intervention 
is inappropriate, the study plan is violated, or  for administrative and/or  other safety reasons. 
A participant must be discontinue d from study intervention but cont inue to be monitored in the 
study for any of the fo llowing reasons:  
1. The participant or participan t’s legally acceptable representa tive requests to discontinue 
study intervention.  
2. Any occurrence of another maligna ncy that requires treatment.  
3. Unacceptable AEs or toxicities  
4. The participant interrupts st udy intervention administration for >28 consecutive days  
5. The participant has a medical condition or personal circumstance which, in the opinion of 
the investigator, placed the participant at unnecessary risk from continued administration 
of study intervention.  
6. The participant has a confirmed positive seru m or highly-sensitive urine pregnancy test.  
 15A participant must be withdraw n from the study if the particip ant or participant’s legally 
acceptable representative withdraws consent from the study. If a particip ant withdraws from the 
study, they will no longer receive st udy intervention or be followed at scheduled protocol visits.  
Lost to Follow-up 
If a participant fails to retu rn to the clinic for a required study vi sit and/or if the site is unable to 
contact the participant, the following procedures are to be performed:  
1. The site must attempt to contact the partic ipant and reschedule the missed visit. If the 
participant is contacted, th e participant should be counseled on the importance of 
maintaining the protocol-sp ecified visit schedule.  
2. The investigator must make every effort to regain contact with th e participant at each 
missed visit (e.g. telephone  calls and/or a certified letter  to the participant’s last known 
mailing address or locally equivalent me thods). These contact attempts should be 
documented in the particip ant’s medical record.  
3. Note: A participant is not considered lost to follow-up until the last scheduled visit for the 
individual participant. The missing data fo r the participant will be managed via the 
prespecified statistical data ha ndling and analysis guidelines.  
5.0 TRIAL INTERVENTIONS 
5.1 Pre-intervention Testing 
Once consent is obtained, if not already performed patients will ha ve a CT or MRI of the Abdomen 
and Pelvis and a CT of the Chest to determin e extent of disease. They will also undergo a 
laparoscopy or mini-laparotomy for peritoneal  carcinomatosis index (PCI) staging and pre-
treatment tissue biopsy. The la paroscopic surgery is  performed under gene ral anesthesia, and 
involves inserting a 5 or 10 mm camera inside the perit oneal cavity to visually assess the peritoneal 
disease burden. Tissue biopsy is obtained by inse rting a second 5 mm port and biopsying one or 
multiple areas of diseased peritoneum. Each bi opsy site will be clearly marked by location for 
pathological identification. Patient s with extensive prior surgery th at precludes a safe laparoscopy 
could undergo a mini-laparoto my, in which a small incision is made to assess the burden of disease 
in the peri-incisional area. This laparoscopy or min i-laparotomy is standard of care for patients 
with peritoneal mesothelioma w ho are considered for CRS/HIPEC. 
 
5.2 Neoadjuvant Nivolumab and Ipilimumab 
5.2.1 Drug Supply 
Both nivolumab and ipilimumab will be  obtained through commercial drug supply.  
 
5.2.2 Dose Selection 
Neoadjuvant nivolumab is deliver ed at a dose of 3 mg/kg over 30 minutes every 21 days via IV 
infusion on day 1 and day 22 of each 42-day cycle for 2 doses (1 cycle). 
 16Neoadjuvant ipilimumab is deliver ed at a dose of 1 mg /kg over 30 minutes ev ery 42 days via IV 
infusion on day 1 of each 42-day cycle for 1 dos e (1 cycle). When given on the same day as 
nivolumab, ipilimumab is to be gi ven following nivolumab infusion.  
 
5.2.3 Dose Modification 
Adverse events (both non-serious and serious) as sociated with nivolumab or ipilimumab exposure 
may represent an immunologic etio logy. These adverse events may occur shortly after the first 
dose or several months after the last dose of treatment. No dose reduc tion for nivolumab or 
ipilimumab is recommende d. In general, withhold nivolumab and ipilimumab for severe (Grade 
3) immune-mediated adverse reactions. Permanently discontinue the agents for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated 
reactions that require  systemic immunosuppressive treatme nt, or an inab ility to reduce 
corticosteroid dose to 10 mg or less of predni sone or equivalent per day within 12 weeks of 
initiating steroids.   Dosage modifications for nivolum ab or ipilimumab in combinat ion for adverse reactions that 
require management different fr om these general guidelines are summarized in the prescribing 
information (Appendix).  Dosing interruptions are permitted in  the case of medical / surgical events or logistical reasons not 
related to study therapy (e.g., elect ive surgery, unrelated medical ev ents, patient vacation, and/or 
holidays). Subjects should be placed back on st udy therapy within 3 we eks of the scheduled 
interruption, unless otherwise disc ussed with the Principal Investigator. The reason for interruption 
should be documented in the patient's study record. 
 
5.3 Surgical Intervention 
After completion of 2 cycles of nivolumab and 1 cycle of ipilimumab, patients will undergo 
restaging CT or MRI and labs to  assess disease response. A su rgical re-evalu ation will be 
conducted to determine if patients remain suitab le candidates for surgery. Surgical cytoreduction 
and HIPEC with mitomycin-C will  be performed approximately 2- 6 weeks after the last dose of 
nivolumab, to achieve an adequate cytoreduction of all residual gross tumor. CRS+HIPEC, which 
can be performed via a laparoscopic or an open laparotomy approach, incl udes but is not limited 
to peritonectomy procedures wher eby the parietal peritoneum is resected, omentectomy and other 
visceral resections as necessary to reduce th e tumor burden to minimal residual disease. 
Completeness of cytoreduction and PCI scores w ill be documented. The dose of intraperitoneal 
chemotherapy will be 40 mg of mitomycin in split dosing of 30mg at time 0 and 60 mg at time 60 
minutes, with a complete washout at 90 minutes . Tumor resections from matched sites of the 
original pre-neoadjuvant therapy biopsy will be marked clearly for path ological identification.  
 Patients will be closely monitored for pote ntial complications fo llowing surgery. Major 
complications include death, anastomotic leak, deep  or superficial site infection, anemia, re-
operations, organ failure including re nal failure, cardiac failure or re spiratory failure, neutropenia, 
thromboembolic events, dehydrat ion and failure to thrive. 
 
 175.4 Adjuvant Nivolumab and Ipilimumab 
Following surgery, patients will have 6-8 weeks of recovery prior to the initiation of adjuvant 
immunotherapy. Cross-sectional imaging will be obtai ned prior to starting adjuvant therapy and 
will be repeated every 6 weeks while on therap y. Adjuvant immunotherapy with nivolumab and 
ipilimumab will be administered according to the same dosing and schedule as it was given in the neoadjuvant phase, but with the first cycle to include ni volumab alone.  
The first 2 cycles in the adjuvant phase will incl ude nivolumab delivered at a dose of 3 mg/kg over 
30 minutes every 21 days via IV infusion on day 1 and day 22 of each 42-day cycle for 4 doses (2 
cycles) and ipilimumab delivered at a dose of 1 mg/kg over 30 minutes every 42 days via IV 
infusion on day 22 of each 42-day cycle for 2 doses (2 cycles). When given on the same day as 
nivolumab, ipilimumab is to be given follow ing nivolumab infusion. Following these first 2 
adjuvant cycles, nivolumab will be delivered alone at the same dose, route, and rate every 21 days 
on days 1 and 22 of each 42-day cycle, continuing until 1 year post-operatively.   
6.0 ADDITIONAL METHODOLOGY 
6.1 Trial Blinding/Masking 
This is an open-label trial; therefore, the i nvestigator and subject will know the treatment 
administered. 
6.2 Randomization or Treatment Allocation  
There will be no randomization. All patients that m eet criteria will be enro lled in the single arm. 
6.3 Stratification  
No stratification will be done.  
6.4 Concomitant Medications/Vaccinations (allowed & prohibited)  
Medications or vaccinations speci fically prohibited in the exclusi on criteria are not allowed during 
the ongoing trial.  If there is a clinical indication for one of these or other medications or 
vaccinations specifically prohibited during the trial, discontinuation from trial therapy or 
vaccination may be required. The final decision on any supportive therapy or vaccination rests 
with the investigator and/or the subject's pr imary physician.  
 
6.4.1 Acceptable Concomitant Medications 
All treatments that the treating investigator co nsiders necessary for a subject’s welfare may be 
administered at the discretion of the treating inves tigator in keeping with the community standards 
of medical care.  All concomit ant medication will be recorded on the case report form (CRF) 
including all prescription, over- the-counter (OTC), herbal suppl ements, and IV medications and 
fluids.  If changes occur during the trial period, docume ntation of drug dosage, frequency, route, 
and date may also be included on the CRF. 
 18All concomitant medications received within 28 da ys before the first dose of trial treatment and 
30 days after the last dose of trial treatment should be recorded.  Concomitant medications 
administered after 30 days after the last dose of trial tr eatment should be recorded as well. 
6.4.2 Prohibited Concomitant Medications 
Subjects are prohibited from receiving the following therapies during the Treatment Phase of this 
trial: 
 Immunotherapy not specif ied in this protocol 
 Chemotherapy not specifie d in this protocol 
 Investigational agents not specified in this protocol 
 Radiation therapy   
 Live vaccines within 30 days prior to the first dose of trial treatment and while participating 
in the trial.  Examples of live vaccines in clude, but are not limite d to, the following: 
measles, mumps, rubella, vari cella/zoster, yellow fever, ra bies, BCG, and typhoid vaccine.  
 Systemic glucocorticoids while on nivolumab and ipilimumab for a ny purpose other than 
to modulate symptoms from an event of cl inical interest of suspected immunologic 
etiology.  The use of physiologic doses of  corticosteroids may be approved after 
consultation with the Principal Investigator. 
Subjects who, in the assessment by the treating investigator, re quire the use of any of the 
aforementioned treatments for clin ical management should be rem oved from the trial.  Subjects 
may receive other medications th at the treating investigator d eems to be medically necessary. 
The Exclusion Criteria describes other medica tions that are prohibited in this trial. 
There are no prohibited therapies duri ng the Post-Treatment Follow-up Phase. 
6.5 Supportive Care Guidelines 
Subjects should receive appropriate  supportive care measures as de emed necessary by the treating 
investigator.  Suggested supporti ve care measures for the management of ad verse events with 
potential immunologic etiology are outlined below.  Where appropriate, these guidelines include 
the use of oral or intravenous treatment with cor ticosteroids as well as a dditional anti-inflammatory 
agents if symptoms do not improve with administr ation of corticosteroids.  Note that several 
courses of steroid tapering may be necessary as symptoms may worsen when the steroid dose is 
decreased. For each disorder, attempts should be made  to rule out other caus es such as metastatic 
disease or bacterial or viral infection, which might require additional supportive care. The 
treatment guidelines are intended to be applied when  the treating investigator determines the events 
to be related to the study treatment.  
It may be necessary to perform conditional pro cedures such as bronchoscopy, endoscopy, or skin 
photography as part of ev aluation of the event.  
 19 Pneumonitis :  
o For Grade 2 events , treat with systemic corticoste roids. When symptoms improve 
to Grade 1 or less, steroid taper should be started and contin ued over no less than 4 
weeks. 
o For Grade 3-4 events , immediately treat with intravenous steroids.  Administer 
additional anti-inflammatory  measures, as needed. 
o Add prophylactic antibiotics for opportunistic  infections in the case of prolonged 
steroid administration. 
 Diarrhea/Colitis :  
Subjects should be carefully mon itored for signs and symptoms of enterocolitis (such as diarrhea, 
abdominal pain, blood or mucus in  stool, with or without fever) an d of bowel perforation (such as 
peritoneal signs and ileus).   
o All subjects who experience diarrhea/colitis should be advised to drink liberal 
quantities of clear fluids.  If sufficient oral fluid intake  is not feasible, fluid and 
electrolytes should be substituted via IV in fusion.  For Grade 2 or higher diarrhea, 
consider GI consultation and endoscopy to confirm or rule out colitis. 
o For Grade 2 diarrhea/colitis  that persists greater than 3 days, administer oral 
corticosteroids.  
o For Grade 3 or 4 diarrhea/colitis  that persists > 1 wee k, treat with intravenous 
steroids followed by high dose oral steroids.   
o When symptoms improve to Grade 1 or le ss, steroid taper should be started and 
continued over no less than 4 weeks. 
 Type 1 diabetes mellitus (if new onset, in cluding diabetic ketoacidosis [DKA]) or ≥ 
Grade 3 Hyperglycemia, if asso ciated with ketosis (ketonuria) or metabolic acidosis 
(DKA) 
o For T1DM  or Grade 3-4  Hyperglycemia 
 Insulin replacement therapy is recommended for Type I diabetes mellitus 
and for Grade 3-4 hyperglycemia associ ated with metabolic acidosis or 
ketonuria.  
 Evaluate patients with serum glucose and a metabolic panel, urine ketones, 
glycosylated hemoglob in, and C-peptide.  
 Hypophysitis : 
 20o For Grade 2  events, treat with corticosteroids. When symptoms improve to Grade 
1 or less, steroid taper should be started and continued over no less than 4 weeks. 
Replacement of appropriate hormones may be required as the steroid dose is tapered. 
o For Grade 3-4  events, treat with an initial dose of IV corticosteroids followed by 
oral corticosteroids. When symptoms im prove to Grade 1 or less, steroid taper 
should be started and con tinued over no less than 4 weeks. Replacement of 
appropriate hormones may be required  as the steroid dose is tapered. 
 Hyperthyroidism or Hypothyroidism :  
Thyroid disorders can occur at an y time during treatment. Monitor pa tients for changes in thyroid 
function (at the start of treatment , periodically during treatment, a nd as indicated based on clinical 
evaluation) and for clini cal signs and symptoms of thyroid disorders. 
o Grade 2  hyperthyroidism events (and Grade 2-4  hypothyroidism): 
 In hyperthyroidism, non- selective beta-blocker s (e.g. propranolol) are 
suggested as initial therapy. 
 In hypothyroidism, thyroid horm one replacement therapy, with 
levothyroxine or liothyr oinine, is indicated per standard of care. 
o Grade 3-4  hyperthyroidism  
 Treat with an initial dose of IV corticosteroid followed by oral 
corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.  Replacement of 
appropriate hormones may be required  as the steroid dose is tapered. 
 Hepatic : 
o For Grade 2  events, monitor liver function tests more frequently until returned to 
baseline values (consider weekly). 
 Treat with IV or oral corticosteroids 
o For Grade 3-4  events, treat with intravenous co rticosteroids for 24 to 48 hours.  
o When symptoms improve to Grade 1 or le ss, a steroid taper should be started and 
continued over no less than 4 weeks. 
 Renal Failure or Nephritis : 
o For Grade 2  events, treat with corticosteroids. 
o
 For Grade 3-4  events, treat with syst emic corticosteroids. 
 21o When symptoms improve to Grade 1 or le ss, steroid taper should be started and 
continued over no less than 4 weeks.  
Management of Infusion Reactions : 
Discontinue nivolumab and ipilimumab in patients  with severe (Grade 3) or life-threatening 
(Grade 4) infusion-related reactions. Interrupt or sl ow the rate of infusion in patients with mild 
(Grade 1) or moderate (Grade 2) infusion-rela ted reactions.  
6.6 Diet/Activity/Other Considerations 
6.6.1 Diet 
Subjects should maintain a normal diet unless modi fications are required to  manage an AE such 
as diarrhea, naus ea or vomiting. 
6.6.2 Contraception 
Nivolumab and ipilimumab may have adverse effects on a fetus in utero.  Furthermore, it is not 
known if nivolumab or ipilimumab ha ve transient adverse effects on  the composition of sperm.  
Non-pregnant, non-breast-feeding wo men may be enrolled if they ar e willing to us e 2 methods of 
birth control or are considered hi ghly unlikely to conceive.  Highly unlikely to conceive is defined 
as 1) surgically sterilized, or 2) postmenopausal (a woman who is ≥ 45 years of age and has not 
had menses for greater than 1 ye ar will be considered postmenopausal), or 3) not heterosexually 
active for the duration of the st udy.  The two birth control methods  can be either two barrier 
methods or a barrier method plus  a hormonal method to prevent pr egnancy. Subjects should start 
using birth control from study Vis it 1 throughout the study period up to  120 days afte r the last dose 
of study therapy.   The following are considered adequate barrier me thods of contraception:  diaphragm, condom (by 
the partner), copper intrauterine device, sp onge, or spermicide.  Appropriate hormonal 
contraceptives will include any registered and ma rketed contraceptive agent that contains an 
estrogen and/or a progesterone agen t (including oral, subcutaneous, intrauterine, or intramuscular 
agents).  Subjects should be informed th at taking the study medication may involve unknown risks to the 
fetus (unborn baby) if pregnancy were to occur dur ing the study.  In order to participate in the 
study, they must adhere to the contraception requir ement (described above) for the duration of the 
study and during the follow-up peri od. If there is any question that  a subject will not reliably 
comply with the requirements fo r contraception, that subject shoul d not be entered into the study. 
 
6.6.3 Use in Pregnancy 
If a subject inadvertently becomes pregnant wh ile on study, the subject will immediately be 
removed from the study.  The treating investigator a nd/or their designee will contact the subject at 
least monthly and document the subject’s status until the pre gnancy has been completed or 
terminated.  The outcome of the pregnancy will be reported to the Principal Investigator. 
 22If a male subject impregnates his female partner the study personnel at  the site must be informed 
immediately and the pregnancy reported to the Pr incipal Investigator and followed as described 
above.  
6.6.4 Use in Nursing Women 
There are no data on the presence of nivolumab or ipilimumab in human milk, the effects on the 
breastfed child, or the effects on milk productio n. Because of the potential for serious adverse 
reactions in breastfed children and since many dr ugs are excreted in human milk, subjects who are 
breast-feeding are not el igible for enrollment. 
 
6.7 Subject Withdrawal/Discontinuation Criteria 
Subjects may withdraw consent at  any time for any reason or be dropped from the trial at the 
discretion of the principal and/or  treating investigator should a ny untoward effect occur.  In 
addition, a subject may be withdraw n by the principal and/or treati ng investigator if enrollment 
into the trial is inappropriate, the trial plan is violated, or for administra tive and/or other safety 
reasons.  Further details ar e described in Section 4.7. 
 
6.8 Clinical Criteria for Early Trial Termination 
Early trial termination will be the result of the criteria specified below: 
1. Quality or quantity of data recording is inaccurate or incomplete 
2. Poor adherence to protocol and regulatory requirements 
3. Incidence or severity of adverse drug reaction in this or other studi es indicates a potential health 
hazard to subjects 
4. Plans to modify or discontinue the development of the study drug 
5. If 2 patient deaths attributed to the investig ational drug are seen in the 30 days following 
surgery. The relationship of the investigational drug to the mortality will be determined by the 
treating medical oncolo gist and surgeon.  
6. Assuming a major complication rate of 10% fr om the combination immunotherapy (Taioli, 
2015), the trial will be halted if any major complication which is attributed to the 
investigational drug occurs in th e first two patients, or in 3 cases among the first 11 patients, 
or in any 4 patients during the course of the tria l. In order for the trial to be halted, these 
complications must be determined to result from the investigational drug as will be determined by the treating oncologist and su rgeon. A composite adverse ev ent of major complications 
defined as the occurrence of any ventricula r arrhythmia requiring treatment, hemorrhage 
requiring re-operation, acute resp iratory distress syndrome (ARD S), pneumonia, reintubation, 
placement of a tracheostomy, pu lmonary embolus, empyema, seps is, intra-abdominal sepsis, 
myocardial infarction and unexpected return  to the operating room will be monitored 
sequentially.  
 237.0 TRIAL PROCEDURES 
7.1 Flow Chart – Schedule of Events 
7.1.1 Flow Chart for Screening, Neoadjuvant, and Surgery Phases 
Table 2.  Trial Flow Chart of Screening, Neoadjuvant, and Surgery Phases 
 24 
 Trial Phase: Screening 
Phase Neoadjuvant Treatment Phase Pre-Surgery 
Phase Surgery Phase Post-Surgery 
Recovery Phase 
 Screening 
(Visit 1) C1 D1 C1 D22C 4 Weeks 3 Weeks 3-4 Weeks 
Scheduling Window (Days): -28 to -1  ± 3    
Administrative Procedures 
Informed Consent X      
Inclusion/Exclusion Criteria X   X X  
Demographics and Medical 
History X   X X  
Prior and Concomitant 
Medication Review X X X X X  
Interventions 
Nivolumab Administration  X X    
Ipilimumab Administration  X     
Surgery     X  
Clinical Procedures/Assessments 
Review Adverse Events X X X X   
Full Physical Examination X X X X X  
Height X      
Vital Signs and Weight X X X X X  
ECOG Performance Status X X X X X  
EORTC QOL C30 X   X  X 
Surgeon Assessment X   X   
Medical Oncology Assessment X X X X   
Laboratory Procedures/Assessments: analysis performed by LOCAL laboratory a 
Pregnancy Test – Urine or Serum 
-HCG X      
CBC with Differential  X X X X   
Comprehensive Serum Chemistry 
Panel X X X X   
INR, PTT X   X   
Urinalysis X      
TSH (reflex T3, T4 if abnormal) X X  X   
Efficacy Measurements b 
Tumor Imaging with CT/MRI X   X   
CA-125 X   X   
Circulating tumor cells X   X   
Tumor Biopsies/Archival Tissue Collection/Correlative Studies Blood 
Laparoscopy for tissue and PCI 
score assessment X      
Correlative Studies Blood 
Collection c X X  X X  
a. Screening  lab tests to be performed  within 14 days before first dose. After Cycle 1, pre‐dose lab procedures  can be conducted  <72 hours before dosing.  
b. For CT scans, scheduling  window is +/‐ 7 days.  
c. Serum mesothelin  and osteopontin  will be obtained at the times of tumor imaging and upon tumor progression.   
 257.1.2 Flow Chart for Adjuvant and Post-Treatment Phases 
Table 3. Trial Flow Chart of Adjuvant and Post-Treatment Phases  
Trial Period: Adjuvant Therapy Phase End of 
Treat-
ment Post-Treatment Phase 
Treatment Week/Title:     Repeat x 1 year 
from surgery Discon Safety 
Follow-
up Follow 
Up 
Visits Survival 
Follow-Up C1 
D1 C1 
D22 C2 
D1 C2 
D22 C1 
D1 C1 
D22 C2 
D1 C2 
D22 
Scheduling Window (Days)c:  ± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 
3 At 
time of 
Discon 30 days 
post 
discon Every 
12 wks 
post 
discon Every 12 
weeks 
Nivolumab Administration X X X X X X X X     
Ipilimumab Administration  X  X         
Prior and Concomitant 
Medication Review X X X X X X X X X X   
Post-study anticancer therapy 
status         X     
Survival Status         X X X X 
Review Adverse Events X X X X X X X X X X X X 
Full Physical Examination X X X X X X X X     
Vital Signs and Weight X X X X X X X X     
ECOG Performance Status X X X X X X X X     
EORTC QOL C30 X  X  X  X  X X   
Laboratory Parameters 
CBC with Differential X X X X X X X X     
Comprehensive Serum 
Chemistry Panel X X X X X X X X     
TSH (reflex T3, T4 if 
abnormal) X  X  X  X      
Efficacy Measurement 
Tumor Imaging with CT scan 
every 12 weeks c
 X  X  X  X      
CA-125 X  X  X  X      
Circulating tumor cells X  X  X  X      
Correlative Lab 
Correlative Studies Blood 
Collection a,b X    X    X    
a. Both tumor imaging and correlative  studies to be repeated after every 6  weeks. 
b. Serum mesothelin  and osteopontin  will be obtained at the times of tumor imaging and upon tumor 
progression.   
c. For CT scans, the scheduling  window is +/‐ 7 days 
 
The Trial Flow Chart summarizes th e trial procedures to be perform ed at each visit.  Individual 
trial procedures are described in detail below.  It may be necessary to perform these procedures 
at unscheduled time points if deemed c linically necessary by the investigator. 
 26 
7.2 Informed Consent 
The Investigator must obtain doc umented consent from each potential subject prior to participating 
in a clinical trial.  
Consent must be documented by the subject’s date d signature or by the subject’s legally acceptable 
representative’s dated signature  on a consent form along with th e dated signature of the person 
conducting the consent discussion.   A copy of the signed and dated consent form should be  given to the subject before participation in 
the trial.  The initial informed consent form, any subsequent  revised written informed consent form and any 
written information provided to the subject must receive the IRB/E RC’s approval/favorable 
opinion in advance of use.  The subject or hi s/her legally acceptable re presentative should be 
informed in a timely manner if new information b ecomes available that ma y be relevant to the 
subject’s willingness to continue participation in the trial.  The communication of this information 
will be provided and documented via a revised c onsent form or addendum to the original consent 
form that captures the subject’s dated sign ature or by the subject’s legally acceptable 
representative’s dated signature.  The informed consent will adhere to IRB/ERC requ irements and applicable  laws and regulations. 
 
7.3 Inclusion/Exclusion Criteria Review 
All inclusion and exclusion criteria will be revi ewed by the treating investigator or qualified 
designee to ensure that the s ubject qualifies for the trial.  
7.4 Medical History 
A medical history will be obtained by the treating investigator or qualified designee.  Medical 
history will include all active conditions, and a ny condition diagnosed within the prior 10 years 
that are considered to be clinically significant by the Investigator.  Details regarding the disease for which the subject has enrolled in this study will be recorded separately and not listed as medical 
history.   
7.5 Prior and Concomitant Medications Review 
7.5.1 Prior Medications 
The treating investigator or qualified designee will review prior medication use, including any 
protocol-specified washout requirement, and reco rd prior medication take n by the subject within 
28 days before starting the trial.  Treatment for the disease for wh ich the subject has enrolled in 
this study will be recorded separately and not listed as a prior medication.  
 
 277.5.2 Concomitant Medications 
The treating investigator or qua lified designee will record medication, if any, taken by the 
subject during the trial.    
7.6 Disease Details and Treatments 
7.6.1 Disease Details 
The treating investigator or qua lified designee will obtain prio r and current details regarding 
disease status.   
7.6.2 Prior Treatment Details 
The treating investigator or quali fied designee will review all prior cancer treatments including 
systemic treatments, radiation and surgeries.  
7.6.3 Subsequent Anti-Cancer Therapy Status 
The treating  investigator or qualified desi gnee will review all new anti -neoplastic therapy initiated 
after the last dose of trial treatment.  If a subjec t initiates a new anti-cance r therapy within 30 days 
after the last dose of trial treatment, the 30-day Safety Follow-up visit should occur before the first dose of the new therapy.  Once new anti-cancer th erapy has been initiated the subject will move 
into survival follow-up.  
7.7 Adverse Event (AE) Monitoring 
The treating  investigator or qualified designee will assess each subject to evaluate for potential 
new or worsening AEs as specified in the Trial Flow Chart and more frequently if clinically indicated.  Adverse experiences will be graded and recorded throughout the study and during the 
follow-up period according to CTCAE (v5.0). Toxiciti es will be characterized  in terms regarding 
seriousness, causality, toxicity grading, and action ta ken with regard to trial treatment.  
7.8 Full Physical Exam 
The treating  investigator or qualified de signee will perform a complete  physical exam during the 
screening period and as indicated in the Trial Flow Chart.  Clinically signi ficant abnormal  findings 
should be recorded as medical history.   
7.9 Vital Signs 
The treating  investigator or qualified designee will take vital signs at screening, prior to the 
administration of each dose of tr ial treatment and at tr eatment discontinuation as specified in the 
Trial Flow Chart. Vital signs should include temp erature, pulse, respiratory rate, weight and blood 
pressure.  Height will be measured at screening only. 
 287.10 Eastern Cooperative Oncology Gr oup (ECOG) Performance Scale 
The treating investigator or qua lified designee will asse ss ECOG status at sc reening, prior to the 
administration of each dose of trial treatment and discontinuation of trial treatment as specified in the Trial Flow Chart.   
7.11 Tumor Imaging and Assessment of Disease 
CT or MRI scans will be obtained at baseline . After completion of neoadjuvant nivolumab + 
ipilimumab treatment a CT or MRI imaging will ag ain be repeated after completion of surgery 
(prior to starting adjuvant immunotherapy), and re peated every 6 weeks while on adjuvant therapy 
and every 3 months for 1 year  after completing treatment. 
7.12 Tumor Tissue Collection and Correlative Studies Blood Sampling 
Tumor tissue will be obtained at laparoscopy and at  surgical resection. Correlative studies blood 
sampling for SRMP, osteopontin, CA-125, and circul ating tumor cells will be obtained per Trial 
Flow Chart schedule.    
7.13 Laboratory Procedures/Assessments 
Details regarding specific laboratory procedures/assessments to be performed in this trial are 
provided below Laboratory Safety Evaluati ons (Hematology, Chemistry and Urinalysis) 
Laboratory tests for hematology, chemistry, urinalys is, and others are specified in Table 4.   
Table 4.  Laboratory Tests  
Hematology Chemistry Urinalysis Other 
Hematocrit Albumin Blood Serum β-human 
chorionic 
gonadotropin  (β-hCG)  
† 
Hemoglobin Alkaline phosphatase Glucose PT (INR) 
Platelet count Alanine aminot ransferase (ALT) Protein PTT 
WBC (total and differential) Aspartate amin otransferase (AST) Specific gravity  Total 
thriiodothyronine (T3) 
Red Blood Cell Count Carbon Dioxide (CO 2 or bicarbonate)  Microscopic exam (If abnormal 
results are noted)  Free thyroxine (T4) 
Absolute Neutrophil Count Calcium Urine pregnancy test † Thyroid stimulating 
hormone (TSH) 
Absolute Lymphocyte Count Chloride   Blood for correlative 
studies 
 Glucose   
 Potassium   
 Sodium    
 Total Bilirubin    
 Total protein    
 29Hematology Chemistry Urinalysis Other 
 Blood Urea Nitrogen    
† Perform on women of childbearing potential only. If urine preg nancy results cannot be confirmed as negative, a serum pregnancy  test 
will be required.   
 
Laboratory tests for screening should be perform ed within 14 days prior to the first dose of 
treatment.  After Cycle 1, pre-dos e laboratory procedures can be conducted up to 72 hours prior to 
dosing.  Results must be reviewed by the treatin g investigator or qualifi ed designee and found to 
be acceptable prior to each dose of trial treatment.  
 
7.14 Safety Follow-Up Visit 
The mandatory Safety Follow-Up Visit should be  conducted approximately 30 days after the last 
dose of trial treatment or before the initiation of a new anti-cancer treatment, whichever comes 
first.  All AEs that occu r prior to the Safety Foll ow-Up Visit should be record ed.  Subjects with an 
AE of Grade > 1 will be followed until the resolu tion of the AE to Grade 0-1 or until the beginning 
of a new anti-neoplastic therapy, whichever occurs first.  SAEs that occur within 90 days of the 
end of treatment or before initiation of a new anti-cancer treatment should also be followed and 
recorded.    
7.15 Follow-up Visits 
Subjects who discontinue trial treatment for a reas on other than disease pr ogression will move into 
the Follow-Up Phase and should be assessed ev ery 3 months by radiologi c imaging to monitor 
disease status.  Every effort s hould be made to collect informat ion regarding disease status until 
the start of new anti-neoplastic therapy, disease progression, death, or end of the study. Information 
regarding post-study anti-ne oplastic treatment will be collecte d if new treatment is initiated. 
 
7.16 Survival Follow-up 
Once a subject experiences confirmed disease progr ession or starts a new anti-cancer therapy, the 
subject moves into the survival follow-up pha se and should be contac ted by telephone every 12 
weeks to assess for survival status until death, w ithdrawal of consent, or the end of the study, 
whichever occurs first.  
7.17 Assessing and Recording Adverse Events 
7.17.1  Adverse Event Characteristics  
 CTCAE term (AE description) and grade:  The descriptions and grading scales 
found in the revised NCI Common Terminology Criteria for Adverse Events 
(CTCAE) version 5.0 will be utilized for AE  reporting.  All appropriate treatment 
areas should have access to a copy of the CTCAE version 5.0.  A copy of the CTCAE version 5.0 can be downloaded from the CTEP web site 
http://ctep.cancer.gov/proto colDevelopment/electronic_ applications/ctc.htm 
 
 Attribution  of the AE: 
 30- Definite (5) – The AE is clearly related  to the study treatment. 
- Probable (4) – The AE is likely related to the study treatment. 
- Possible (3) – The AE may be related  to the study treatment. 
- Unlikely (2) – The AE is doubtfully related to the study treatment. 
- Unrelated (1) – The AE is clearly NOT related  to the study treatment.  
 
7.17.2  Adverse Event Definitions 
7.17.2.1  Adverse Event 
An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject ad ministered a pharmaceutical product and which does not necessarily have 
to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for ex ample), symptom, or disease 
temporally associated with the us e of a medicinal product or protocol-specified procedure, whether 
or not considered related to the medicinal product or protocol-speci fied procedure.  Any worsening 
(i.e., any clinically significant adverse change in frequency and/ or intensity) of a preexisting 
condition that is temporally  associated with the use of the study treatment, is  also an ad verse event. 
 Changes resulting from normal growth and developm ent that do not vary significantly in frequency 
or severity from expected levels are not to be considered adverse events.  Examples of this may 
include, but are not limited to, t eething, typical crying in infants a nd children and onset of menses 
or menopause occurring at a phys iologically appropriate time. 
 Adverse events may occur during the course of the use of the study treatment in clinical trials or 
within the follow-up period specifi ed by the protocol, or prescrib ed in clinical practice, from 
overdose (whether accidental or intenti onal), from abuse and from withdrawal. 
 
Adverse events may also occur in screened subjec ts during any pre-allocati on baseline period as a 
result of a protocol-specified intervention, including wa shout or discontinuati on of usual therapy, 
diet, placebo treatment or a procedure.  Progression of the cancer unde r study is not considered  an adverse event unle ss it is considered to 
be drug related by the treating investigator. 
 All adverse events will be r ecorded from the time the consent form is signed through 30 days 
following cessation of treatment and at each examination on the Adverse Event case report 
forms/worksheets.   
7.17.2.2  Serious Adverse Event  
An adverse event is considered serious if it results in ANY 
of the following outcomes:  
1) Death 
2) Life-threatening (e.g. places subjec t at immediate risk of death, this does not include events 
that might have caused death if th ey occurred a greater severity) 
3) Inpatient hospitalization or prolonga tion of existing hos pitalization for ≥ 24 hours  
 314) A persistent or significant incapacity or subs tantial disruption of the ability to conduct 
normal life functions  
5) A congenital anomaly/birth defect.  
 
7.17.2.3  Adverse Reactions 
An adverse event is considered to be an adverse reaction if there is evidence to suggest a causal 
relationship to the study agent.  This may in clude a single occurrence of an event strongly 
associated with drug exposure (e.g. Stevens-Jo hnson Syndrome), one or more occurrence of an 
event otherwise uncommon is the study population, or an aggregate analysis of specific events 
occurring at greater th an expected frequency. 
 
7.17.3       Evaluating Adverse Events 
An investigator who is a qualified physician will evaluate all adverse events according to the NCI 
Common Terminology for Adverse Events (CTCAE ), version 5.0. Any adverse event which 
changes CTCAE grade over the course of a given ep isode will have each change of grade recorded 
on the adverse event case report forms/worksheets.  All adverse events regardless of CTCAE grad e must also be evaluated for seriousness.
 
 
 
 7.17.4  Responsibility for Reporting Adverse Events 
All Adverse Events will be reported to regulat ory authorities, IRB/IECs  and investigators in 
accordance with all applicable global laws and regulations.  
 8.0 STATISTICAL ANALYSIS PLAN 
8.1 Primary Endpoint 
The primary endpoint in this st udy is Major Pathologic Response (M PR), defined as presence of 
<=10% residual viable tumor in the resected su rgical specimen. The proportion of patients who 
achieve an MPR will be reported (MPR rate), al ong with an exact 95% confidence interval. 
Sample size considerations: A total of 37 patient s will be enrolled, with the goal to enroll 18-19 
patients per year in 2 consecutive  years. This sample size will  provide 80% power  to detect a 
significant increase in MPR rate of at least 40% using the one-sided binomia l test with the null 
hypothesis H
0:p = 0.5 against the alternative hypothesis H a:p > 0.5 corresponding to an actual MPR 
rate of ~0.7 or higher.   
8.2 Secondary Endpoints  
Safety and feasibility will be a ssessed throughout the trial, especially in discussion with the 
surgeon performing the cytoreductive surgery. Advers e events will be summarized by type, grade, 
and relationship to the study drug.  The trial will be disc ontinued if the 30-day mortality occurs in 
two patients and the cause of death is determined to be related to the investigational agent by the 
treating medical oncologist and surgeon. Refer to section 6.8 for additional clinical criteria for 
early trial termination.   Analyses to address the secondary objectives will be pr imarily descriptive in nature.  Progression-
free survival (PFS) and overall survival (OS) wi ll be estimated using the Kaplan-Meier method 
with qualitative assessment of th e emergence of a tail at the end of the curve as evidence of long-
term survival, which is not seen in this disease despite aggressive multimodality therapy.  Median event times will be determined as the time at which the Kaplan-Meier curve falls below 50%.   
The objective response rate to neoadjuvant ni volumab + ipilimumab ba sed on cross-sectional 
imaging pre- and post-treatment wi ll be determined along with an exact 90% confidence interval. 
8.3 Exploratory Endpoints 
CD8 tumor infiltrating lymphocytes (TILs) will be assessed by % of tumor showing infiltration 
and calculation of CD8 TIL density in the pre- and post-treatment biopsy specimens. An increase 
in the TIL density will be termed a TIL-response  and correlated with TCIP response using Pearson 
or Spearman rank correlation coefficients.  
Presence of additional patholog ic markers, including CD3, CD4, CD68, and CD20 will be assessed 
in pre- and post-treatment tissue samples. Results will be descriptive and presented in tabular form.  
Changes in PD-L1 expression comp ared between the pre- and pos t-treatment tissue samples will 
be determined using IHC and ma ss spectrometry. Ordinal IHC data  will be assessed using the 
 
 
 
 Wilcoxon signed-rank test. Changes in other con tinuous immune response and biomarker values 
will be analyzed using paired t-tests.    Analysis of variance for repeated measures will be performed to evaluate changes in serum mesothelin and osteopontin  levels over time. 
 9.0 LABELING, PACKAGING, STORAGE A ND RETURN OF CLINICAL SUPPLIES 
9.1 Investigational Product  
The investigator shall take respons ibility for and shall take all step s to maintain appropriate records 
and ensure appropriate supply, storage, handling, distribution and usage of investigational product 
in accordance with the protocol and any applicable laws and regulations. 
 
9.2 Packaging and Labeling Information 
Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements. 
 
9.3 Clinical Supplies Disclosure 
This trial is open-label. Drug identity (nam e, strength) is include d in the label text. 
 
9.4 Storage and Handling Requirements 
Clinical supplies must be stored in a secure, limited-access location under  the storage conditions 
specified on the label.    Receipt and dispensing of trial me dication must be recorded by an  authorized person at the trial 
site.  
Clinical supplies may not be used for any purpos e other than that stat ed in the protocol. 
 10.0  ADMINISTRATIVE AND REGULATORY DETAILS 
10.1 Confidentiality 
Individual patient medical inform ation obtained as a result of this  study is considered confidential 
and disclosure to third parties is  prohibited with the exceptions noted below. Patient confidentiality 
will be ensured by using patient identification code numbers. Treatment data may be given to the patient’s personal physician or to other appropriate  medical personnel responsible for the patient’s 
welfare. Data generated as a result of the study need to be available fo r inspection on request by 
the participating physicians, the Drug Manufactur er’s representatives, by the IRB and the 
regulatory authorities.  
10.2 Compliance with Financial Disclosure Requirements 
Financial Disclosure requirements are outli ned in the US Food and Drug Administration  
 
 
 
 Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54) and will be 
implemented following institutional standards. 
10.3 Compliance with Law, Audit and Debarment 
The trial will be conducted in an efficient an d diligent manner and in conformance with this 
protocol; generally accepted standards of Good C linical Practice (e.g., Inte rnational Conference 
on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use 
Good Clinical Practice: Consolidated Guideline and other ge nerally accepted standards of good 
clinical practice); and all applicable federal, state and local laws, rules and regulations relating to the conduct of the clinical trial. 
10.4 Compliance with Trial Registration and Results Posting Requirements 
Under the terms of the Food a nd Drug Administration Moderni zation Act (FDAMA) and the Food 
and Drug Administration Amendments Act (FDAAA), the Sponsor of the trial is  solely responsible 
for determining whether the trial and its results are subject to the requirements for submission to the Clinical Trials Data Bank, http://www.clin icaltrials.gov.  Inform ation posted will allow 
subjects to identify potentially appropriate trials for their disease conditions and pursue 
participation by calling a central contact number  for further informatio n on appropriate trial 
locations and trial site c ontact information.     
 
10.5 Quality Management System 
The Principal Investigator will ensure that tria l is conducted and data are generated, documented, 
and reported in compliance with the protocol, ac cepted standards of Good Clinical Practice, and 
all applicable federal, state, and local laws, ru les and regulations relating to the conduct of the 
clinical trial.   A quality assurance audit/inspection of this study ma y be conducted by regulatory authorities. The 
quality assurance auditor will have access to all medical records, the investigator’s study-related 
files and correspondence, and the informed c onsent documentation of this clinical study. 
The trial will be monitored in the weekly mesothelioma multidisciplinary conference.  
10.6 Data Management 
Data management will be provided via the cancer clinical trial infrastructure available at the 
University of Chicago (eVELOS). It is the responsi bility of the investigator s to record and verify 
the accuracy of subject data.  11.0  REFERENCES 
Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, 
Holtzman M, Hanna N, Turner K, Beresneva T, Zhu Y. Treatment factors associated 
with long-term survival after cytoreductive surgery and region al chemotherapy for patients with 
malignant peritoneal mesothelio ma. Surgery. 2013 Jun;153(6):779-86.  
 
 
 
 
 Alley E, Molife LR, Santoro A, et al. Clinical safety and efficacy of  pembrolizumab (MK-3475) 
in patients with malignant pleural mesothelioma (MPM): Preliminary results from KEYNOTE-
028. Proc AACR 2015.  
 
Armato SG, Li P, Husain AN et al. Radiologic -pathologic correlation of mesothelioma tumor 
volume. Lung Cancer. 2015 Mar;87(3):278-82. 
 
Armato SG 3rd, Nowak AK. Revised Modified Response Evaluation Criteria in Solid Tumors 
for Assessment of Response in Malignant Pleu ral Mesothelioma (Versi on 1.1). J Thorac Oncol. 
2018 Jul;13(7):1012-1021.  
 
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, 
Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Corn elissen R, Greillier L, Grossi F, Kowalski D, 
Rodríguez-Cid J, Aanur P, Oukessou A, Baudele t C, Zalcman G. First-line nivolumab plus 
ipilimumab in unresectabl e malignant pleural me sothelioma (CheckMate  743): a multicentre, 
randomised, open-label, phase 3 trial.  Lancet. 2021 Jan 30;397(10272):375-386.  
 Blank CU, Rozeman EA, Fanchi LF, Sikorska K, va n de Wiel B, Kvistborg P, Krijgsman O, van 
den Braber M, Philips D, Broeks A, van Thiene n JV, Mallo HA, Adriaansz S, Ter Meulen S, 
Pronk LM, Grijpink-Ongering LG, Bruining A, Gittelman RM, Warren S, van Tinteren H, 
Peeper DS, Haanen JBAG, van Akkooi ACJ, Schumacher TN. Neoadjuvant versus adjuvant 
ipilimumab plus nivolumab in macros copic stage III melanoma. Nat Med. 2018 
Nov;24(11):1655-1661.   Blayney JK, Ceresoli GL, Castagneto B, et al. Re sponse to chemotherapy is predictive in relation 
to longer overall survival in an  individual patient combined-analy sis with pleural mesothelioma. 
Eur J Cancer 2012; 48 (16): 2983-2992.  Bott MJ, Yang SC, Park BJ, Adusumilli PS, Rusch VW, Isbell JM, Downey RJ, Brahmer JR, Battafarano R, Bush E, Chaft J, Forde PM, Jones DR, Broderick SR. Initial results of pulmonary 
resection after neoadjuvant nivolumab in patien ts with resectable non- small cell lung cancer. J 
Thorac Cardiovasc Surg. 2019 Jul;158(1):269-276.  Burt BM, Cameron RB, Mollberg NM , et al. Malignant pleural meso thelioma and the Society of 
Thoracic Surgeons Database: an analysis of surgical morbidity and mortality. J Thorac 
Cardiovasc Surg 2014; 148(1): 30-5.  Campbell N, Kindler HL. Update on malignant pl eural mesothelioma. Semin Respir Crit Care 
Med  2011; 32(1): 102-110.  Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda 
M, Grootscholten C, Beets GL, Snaebjornsson P, Maas M, Mertz M, Veninga V, Bounova G, 
Broeks A, Beets-Tan RG, de Wijkerslooth TR, van Lent AU, Marsman HA, Nuijten E, Kok NF, 
Kuiper M, Verbeek WH, Kok M, Van Leerda m ME, Schumacher TN, Voest EE, Haanen JB. 
Neoadjuvant immunotherapy leads to patholog ical responses in MMR-proficient and MMR-
deficient early-stage colon cancer s. Nat Med. 2020 Apr;26(4):566-576. 
 
 
 
  Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, As kin FB, Niknafs N, Smith KN, Velez MJ, Sauter 
JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, 
Velescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Methews A, Taube JM. Pathologic features of response to neoadjuvant anti-PD-1 resect ed non-small-ce ll carcinoma: a 
proposal for quantitative immune-related patholog ic response criteria (irPRC). Ann Oncol 2018 
Aug 1;29(8):1853-1860.  Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and 
angiogenesis. Cancer Re s. 2012 May 1;72(9):2162-71. 
 Fiegle E, Doleschel D, Koletnik S, Rix A, Wei skirchen R, Borkham-Kamphorst E, Kiessling F, 
Lederle W. Dual CTLA-4 and PD-L 1 Blockade Inhibits Tumor Grow th and Liver Metastasis in a 
Highly Aggressive Orthotopic Mouse Model of  Colon Cancer. Neoplas ia. 2019 Sep;21(9):932-
944.   Gordon GJ, Rockwell GN, Godfrey PA, et al. Va lidation of genomics-ba sed prognostic tests in 
malignant pleural mesothelioma. Clin Cancer Res 2005; 11:4406-14. 
 Hamid O, Robert C, Daud A, et al. Safety a nd Tumor Responses with Lambrolizumab (Anti-PD-
1) in Melanoma. N Engl J Med 2013; 369:134-44.  Harlin H. Meng Y, Peterson AC, et al. Chem okine expression in melanoma metastases 
associated with CD8+ T-cell re cruitment. Cancer Res 2009; 69, 3077–3085. 
 
Hellmann MD, Chaft JE, William WN Jr, Rusch V, Pi sters KM, Kalhor N, Pataer A, Travis WD, 
Swisher SG, Kris MG; University of Texa s MD Anderson Lung Cancer Collaborative Group. 
Pathological response after neoadj uvant chemotherapy in resectab le non-small-cell lung cancers: 
proposal for the use of major pat hological response as a surroga te endpoint. Lancet Oncol. 2014 
Jan;15(1):e42-50.   Helm JH, Miura JT, Glenn JA, Marcus RK , Larrieux G, Jayakrishnan TT, Donahue 
AE, Gamblin TC, Turaga KK, Johnston FM. Cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic  review and 
meta-analysis. Ann Surg Oncol. 2015 May;22(5):1686-93.   Henley SJ, Larson TC, Wu M, et al. Mesothelioma  incidence in 50 states and the District of 
Columbia, United States, 2003-2008. Int J Occu p Environ Health 2013; 19 (1): 1-10.  
 Hjerpe A, Ascoli V, Bedrossian CWM, et al. Guidelines for the cytopathologic diagnosis of 
epithelioid and mixed-type malignant mesothelioma: a s econdary publication. 
Cytopathology2015; 26 (3): 142-156.   Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, 
Wubbenhorst B, Dorfman L, D'Andrea K, Wenz BM, Liu S, Chilukuri L, Kozlov A, Carberry M, 
 
 
 
 Giles L, Kier MW, Quagliarello F, McGettigan S,  Kreider K, Annamalai L, Zhao Q, Mogg R, 
Xu W, Blumenschein WM, Yearley JH, Linett e GP, Amaravadi RK, Schuchter LM, Herati RS, 
Bengsch B, Nathanson KL, Farwell MD, Karakousis  GC, Wherry EJ, Mitchell TC. A single dose 
of neoadjuvant PD-1 blockade predicts clinical outcomes in  resectable melanoma. Nat Med. 
2019 Mar;25(3):454-461.  Husain AN, Colby TV, Ordonez NG, et al. Guide lines for pathologic di agnosis of malignant 
mesothelioma: a consensus statem ent from the Internati onal  Mesothelioma Interest Group. Arch 
Pathol Lab Med 2009; 133 (8): 1317-1331.   Kepenekian V, Elias D, Passot G, Mery E,  Goere D, Delroeux D, Quenet F, Ferron 
G, Pezet D, Guilloit JM, Meeus P, Pocard M, Bereder JM, Abboud K, Arvieux C, Brigand C, Marchal F, Classe JM, Lorimier G, De Chaisemartin C, Guyon F, Mariani  
P, Ortega-Deballon P, Isaac S, Maurice C, Gilly FN, Glehen O; French Network for  
Rare Peritoneal Malignancies (RENAPE). Di ffuse malignant peritoneal mesothelioma: 
Evaluation of systemic chemotherapy with  comprehensive treatm ent through the RENAPE 
Database: Multi-Institutional Retrospectiv e Study. Eur J Cancer. 2016 Sep;65:69-79. doi: 
10.1016/j.ejca.2016.06.002. Epub 2016 Jul 26. PubMed PMID: 27472649.  Kindler HL, Zuo Z, Khatri A, Keck MK, Vigne swaran W, Husain AN, Seiwert TY. T-cell 
inflamed phenotype and PDL1 expression in ma lignant mesothelioma. J Clin Oncol 32:5s, 2014 
(suppl, abstr 7589)  Krug L, Pass H, Rusch V et al. Multicenter phase II trial of neoadjuvant peme trexed plus cisplatin 
followed by extrapleural pneumonectomy and radi ation for malignant pleural mesothelioma.  J 
Clin Oncol. 2009; 27(18):3007-13.  
Miura JT, Johnston FM, Gamblin TC, Turaga KK.  Current trends in the management of 
malignant peritoneal mesothelioma. A nn Surg Oncol. 2014 Nov;21(12):3947-53. doi: 
10.1245/s10434-014-3803-6. Epub 2014 May 20. PubMed PMID: 24841356.  Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda  E, Husain AN, Patel JD, Rose B, Zhang SR, 
Weatherly M, Nelakuditi V, Knight Johnson A, He lgeson M, Fischer D, Desai A, Sulai N, 
Ritterhouse L, Røe OD, Turaga KK, Huo D, Segal J, Kadri S, Li Z, Ki ndler HL, Churpek JE. 
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. J 
Clin Oncol. 2018 Oct 1;36(28):2863-2871.  
Powderly JD, Koeppen H, Hodi FS,  et al. Biomarkers and associa tions with the clinical activity 
of PD-L1 blockade in a MPDL3280A study. J Clin Oncol 2013; 31 (suppl; abstr 3001). 
 Ray M, Kindler HL. Malignant pleural mesothel ioma: an update on biomarkers and treatment. 
Chest 2009; 136(3): 888-896.  
Ribas A, Robert C, Hodi FS, et al Association of  response to programmed death receptor 1 (PD-1) 
blockade with pembrolizumab (MK-3475 ) with an interferon-in flammatory immune gene  signature. J Clin 
Oncol 33, 2015 (suppl; abstr 3001) 
 
 
 
 
 Rusch VW, Giroux D. Do we need a revised stag ing system for malignant  pleural mesothelioma? 
Analysis of the IASLC database. Ann Cardiothoracic Surg 2012; 1(4): 438-448. 
 Saloura, V, Zuo, Z, Koeppen, H, et al. Co rrelation of T-cell inflamed phenotype with 
mesenchymal subtype, expression of PD-L1, a nd other immune checkpoints in head and neck 
cancer. J Clin Oncol 2014;  32:5s, (suppl; abstr 6009) 
 Seiwert TY, McGregor, S, Zuo Z, Khattri A, Hasi na R, Vigneswaran W, Salgia R, Husain A, 
Kindler H. T-cell inflamed phenotype, PD-L1, a nd ICOS expression identify a subgroup of 
malignant mesotheliomas amenable to imm unotherapy approaches. Proc IMIG 2014. 
 Seiwert TY, Burtness, B, Weiss J, Eder JP, Y early J, Murpy E, Nebozhyn M, McClanahan M, 
Ayers M, Lunceford J, Mehra R,Heath K, Ch eng J, Chow LQ, Inflamed-phenotype gene 
expression signatures, and in particular a γ-Interferon signature predict benefit from  
the anti-PD-1 antibody pembrolizumab in PD-L 1+ HNC, ASCO Annual M eeting 2015, abstract 
6017.  Topalian SL, Taube JM, Pardoll DM. Neoa djuvant checkpoint blockade for cancer 
immunotherapy. Science 2020;367(6477).  Turaga KK, Deraco M, Alexander HR. Current  management strategi es for peritoneal 
mesothelioma. Int J Hyperthermia. 2017 Aug; 33(5):579-581. doi: 
10.1080/02656736.2017.1320591. PubMed PMID: 28664790.  Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination 
with cisplatin versus cisplatin alone in patients with malignant  pleural mesothelioma. J Clin 
Oncol 2003; 21 (14): 2636-2644.  White MG, Schulte JJ, Xue L, Berger Y, Schuite voerder D, Vining CC, Kindler HL, Husain A, 
Turaga KK, Eng OS. Heterogeneity in PD-L1 expr ession in malignant peritoneal mesothelioma 
with systemic or intraperitoneal chemot herapy. Br J Cancer. 2021 Feb;124(3):564-566.  
 Wolchok JD, Kluger H, Callahan MK, et al. Nivolu mab plus ipilimumab in  advanced melanoma. 
N Engl J Med 2013; 369:122-33.  Wolchok JD, Hoos A, O’day S, et al. Guidelines for the evaluation of imm une therapy activity in 
solid tumors: immune related response criteria. Clin Cancer Res 2009; 15: 7412 
 Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso  P, Sugarbaker PH. Cytoreductive surgery and 
hyperthermic intraperitoneal ch emotherapy for malignant peri toneal mesothelioma: multi-
institutional experience. J Clin Oncol. 2009 Dec 20;27(36):6237-42. doi: 
10.1200/JCO.2009.23.9640. Epub 2009 Nov 16. PubMed PMID:  19917862  
 
 
 
 Yang Z, Liu M, Yu Y, Chen T, Han Y, Zhu L, Zhao J, Fu X, Cai X. Treatment of stage III non-small cell lung cancer in  the era of immunotherapy: path ological complete response to 
neoadjuvant pembrolizumab and chemotherapy. Transl Lung Cancer Res 2020; 9(5):2059-2073. 
  12.0 APPENDIX 
12.1 ECOG Performance Status 
Grade Descriptio
n 
0 Normal activity. Fully active, able to carry on all pre-disease 
performance without restriction. 
1 Symptoms, but ambulatory. Restri cted in physically strenuous 
activity, but ambulatory and able to  carry out work of a light or 
sedentar y nature (e. g., light housework, office work). 
2 In bed <50% of the time . Ambulatory and capable of all self-care, but 
unable to carry out any work activities. Up and about more than 50% 
of wakin g hours. 
3 In bed >50% of the time. Capable of  only limited self-care, confined 
to bed or chair more than 50% of wakin g hours. 
4 100% bedridden. Completely disabled . Cannot carry on any self-care. 
Totall y confined to bed or chair. 
5 Dead. 
* As published in Am. J. Clin. Oncol.:  Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., 
McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology 
Group. Am J Clin Oncol 5:649-655, 1982. The Eastern Cooperative Onco logy Group, Robert Comis 
M.D., Group Chair. 
 
12.2 Common Terminology Criteria for Adverse Events V5.0 (CTCAE) 
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for 
Adverse Events (CTCAE) version 5.0 will be utilized for adverse event reporting. 
(https://ctep.cancer.gov/proto colDevelopment/elect ronic_applications/ctc.htm#ctc_60 ) 
 
12.3 Prescribing Information 
12.3.1  Nivolumab 
https://www.accessdata.fda.gov/drugsa tfda_docs/label/2018/125554s058lbl.pdf  
 
12.3.2  Ipilimumab 
https://www.accessdata.fda.gov/drugsa tfda_docs/label/2020/125377s110lbl.pdf  
 
12.4 EORTC QOL-C30 Quality of Life Survey 
https://www.eortc.org/app/uploads/site s/2/2018/08/Specimen-QLQ-C30-English.pdf  